secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mineralys Therapeutics, Inc. (MLYS)
CIK:        0001933414
Form:       8-K
Filed at:   2024-01-04T23:59:59+00:00
Accession:  0001933414-24-000002
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mineralys Therapeutics appoints Minji Kim Ph.D. as CBO; splits CFO/CBO roles
----------------------------------------------------------------------------

- Adam Levy remains CFO and Secretary; no longer serves as CBO as of Jan 4, 2024.
- Dr. Kim brings >20 years biotech BD experience including Jounce Therapeutics and Curis.
- Company expects clinical milestones for hypertension drug lorundrostat over next 12–18 months.
- Role split supports expanded operations as Mineralys advances late-stage development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1933414/000193341424000002/0001933414-24-000002-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1933414/000193341424000002/mlys-20240104.htm
  HTML page:      https://secwatch.observer/filing/0001933414-24-000002

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer